TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04587128
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab
Study: NCT00644293
Drug: azithromycin (Zithromax)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 500 mg tablet by mouth once daily for 3 days
Study: NCT00644293
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03206463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
Study: NCT00802360
Drug: Progestrone vaginal insert
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Study: NCT00644293
Drug: azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
Study: NCT04513951
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: phase II
Study: NCT04513951
Drug: L-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: phase II
Study: NCT04546009
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Study: NCT04047875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
Study: NCT04164901
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo oral tablets
Study: NCT02882789
Drug: LCB01-0371
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
Study: NCT02882789
Drug: LCB01-0371 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Crossover designed administration
Study: NCT04379479
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01511614
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine deprived
Study: NCT01511614
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator to varenicline
Study: NCT00501592
Drug: INT-747
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg by mouth once daily, 50 mg by mouth once daily
Study: NCT00501592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00954629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
Study: NCT03350035
Drug: IV Placebo, non-active
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01900171
Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01900171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study: NCT04187508
Drug: AZD8154 nebulizer suspension, 20 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
Study: NCT04187508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
Study: NCT00562497
Drug: Prochymal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochymal® intravenous infusion.
Study: NCT00365105
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
Study: NCT04299503
Drug: Placebo Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
Study: NCT04054479
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
Study: NCT04478071
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once daily for 14 days.
Study: NCT00610350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
Study: NCT01031589
Drug: TMC278 (Rilpivirine) LA; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00397761
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03960411
Drug: Doxycycline 100Mg Capsule
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline capsule
Study: NCT03960411
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule manufactured to mimic doxycycline 100 mg capsule
Study: NCT01160003
Drug: GW870086X
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
Study: NCT01608698
Drug: 30 mcg ethinylestradiol/2 mg chlormadinone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
Study: NCT01608698
Drug: 30 mcg ethinylestradiol/3 mg drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
Study: NCT05368545
Drug: High intensity lipid lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two different regimens of drugs with different effects on LDL lowering
Study: NCT02592720
Drug: cocktail
Normalized name: Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
Study: NCT02851797
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
Study: NCT01160003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
Study: NCT03587428
Drug: Zinc-A toothpaste
Normalized name: monofluorophosphate / potassium nitrate / zinc citrate Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study: NCT03587428
Drug: Zinc-B toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
Study: NCT03861416
Drug: L-arginine 1.4% 500 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Study: NCT03861416
Drug: L-arginine 1.4% 250 ml + placebo 250 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
Study: NCT03861416
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Study: NCT02775591
Drug: DA-9701 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill manufactured to mask DA-9701 30mg Tablet
Study: NCT03402204
Drug: Simvastatin 10 mg
Normalized name: simvastatin 10 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Study: NCT03402204
Drug: Simvastatin 40 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease.
Study: NCT01208961
Drug: Epanova (4 g) and Lovaza (4 g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
Study: NCT01208961
Drug: Lovaza (4 g) and Epanova (4 g)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
Study: NCT02483156
Drug: Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
Study: NCT00061815
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 IV
Study: NCT01639339
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Study: NCT03016377
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
Study: NCT01453205
Drug: MEDI-551 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Study: NCT01453205
Drug: MEDI-551 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Study: NCT00920387
Drug: 200 mcg LSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
Study: NCT00920387
Drug: 20 mcg LSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
Study: NCT02153502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered twice a day over a 10-week period
Study: NCT02662283
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
Study: NCT02407340
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
Study: NCT01996696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo TID x 30-36 months
Study: NCT03475706
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 12 weeks.
Study: NCT02320435
Drug: Other Combination Anti-Cancer Therapies
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: If other anti-cancer therapies were given in combination with pertuzumab as part of the Parent study, patients will receive all treatments at the same dose, schedule and under the same administration guidelines which were in effect at the time of Parent study closure.
Study: NCT04894877
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT02650804
Drug: BPM31510 Nanosuspension Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02633163
Drug: Placebo Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
Study: NCT04597190
Drug: Serotonin-norepinephrine reuptake inhibitor
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribers will prescribe venlafaxine.
Study: NCT02251912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
Study: NCT04890873
Drug: ERX1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
Study: NCT04890873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A suspension containing magnesium hydroxide carbonate in polysorbate
Study: NCT03611699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler
Study: NCT02583685
Drug: PR4 + LDV/SOF + ASV 4 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + SMV 4 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + ASV 6 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + SMV 6 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + ASV 8 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + SMV 8 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + ASV 12 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
Study: NCT02583685
Drug: PR4 + LDV/SOF + SMV 12 wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
Study: NCT03785054
Drug: HTL0014242
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
Study: NCT03785054
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT00974220
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose, 50 mcg of nebulized fentanyl citrate
Study: NCT04097028
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04140500
Drug: RO7247669
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Study: NCT03670030
Drug: ABI-009
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
Study: NCT04296175
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, d1 every 2 or 3 weeks
Study: NCT04296175
Drug: ddCTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg, d1 every 2 weeks
Study: NCT03022097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Study: NCT03710421
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03306979
Drug: N Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.